MedinCell Valuation

Is MEDCL undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of MEDCL when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: MEDCL (€11.36) is trading below our estimate of fair value (€35.93)

Significantly Below Fair Value: MEDCL is trading below fair value by more than 20%.


Key Valuation Metric

Which metric is best to use when looking at relative valuation for MEDCL?

Other financial metrics that can be useful for relative valuation.

MEDCL key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue25.9x
Enterprise Value/EBITDA-18x
PEG Ration/a

Price to Sales Ratio vs Peers

How does MEDCL's PS Ratio compare to its peers?

The above table shows the PS ratio for MEDCL vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average1.5x
EAPI Euroapi
0.2x1.6%€253.6m
BOI Boiron
1.1x1.4%€583.4m
VETO Vetoquinol
2.2x4.4%€1.2b
VIRP Virbac
2.5x7.7%€3.1b
MEDCL MedinCell
23.1x40.2%€326.6m

Price-To-Sales vs Peers: MEDCL is expensive based on its Price-To-Sales Ratio (23.1x) compared to the peer average (1.5x).


Price to Earnings Ratio vs Industry

How does MEDCL's PE Ratio compare vs other companies in the European Pharmaceuticals Industry?

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a12.5%
n/an/an/a
No. of CompaniesPS048121620

Fetching data

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a12.5%
n/an/an/a
No more companies

Price-To-Sales vs Industry: MEDCL is expensive based on its Price-To-Sales Ratio (23.1x) compared to the European Pharmaceuticals industry average (3.1x).


Price to Sales Ratio vs Fair Ratio

What is MEDCL's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

MEDCL PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio23.1x
Fair PS Ratio15.3x

Price-To-Sales vs Fair Ratio: MEDCL is expensive based on its Price-To-Sales Ratio (23.1x) compared to the estimated Fair Price-To-Sales Ratio (15.3x).


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst MEDCL forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Current€11.36
€16.75
+47.4%
21.1%€22.00€12.00n/a5
Apr ’25€9.59
€15.48
+61.4%
22.0%€21.00€12.00n/a5
Mar ’25€9.03
€15.48
+71.4%
22.0%€21.00€12.00n/a5
Feb ’25€8.80
€15.48
+75.9%
22.0%€21.00€12.00n/a5
Jan ’25€7.20
€15.23
+111.6%
14.9%€17.40€12.10n/a3
Dec ’24€6.13
€16.68
+172.0%
19.1%€21.00€12.10n/a4
Nov ’24€5.50
€16.68
+203.2%
19.1%€21.00€12.10n/a4
Oct ’24€6.40
€16.68
+160.5%
19.1%€21.00€12.10n/a4
Sep ’24€6.80
€16.68
+145.2%
19.1%€21.00€12.10n/a4
Aug ’24€6.30
€16.68
+164.7%
19.1%€21.00€12.10n/a4
Jul ’24€6.55
€16.68
+154.6%
19.1%€21.00€12.10n/a4
Jun ’24€6.61
€17.05
+157.9%
17.0%€21.00€13.00n/a4
May ’24€8.88
€15.35
+72.9%
10.2%€18.00€14.00n/a4
Apr ’24€9.81
€15.35
+56.5%
10.2%€18.00€14.00€9.594
Mar ’24€8.47
€14.67
+73.2%
19.6%€18.00€11.00€9.033
Feb ’24€7.63
€14.67
+92.2%
19.6%€18.00€11.00€8.803
Jan ’24€6.18
€14.50
+134.6%
24.1%€18.00€11.00€7.202
Dec ’23€6.16
€14.50
+135.4%
24.1%€18.00€11.00€6.132
Nov ’23€5.39
€14.50
+169.0%
24.1%€18.00€11.00€5.502
Oct ’23€5.37
€14.50
+170.0%
24.1%€18.00€11.00€6.402
Sep ’23€5.10
€14.50
+184.3%
24.1%€18.00€11.00€6.802
Aug ’23€5.12
€14.50
+183.2%
24.1%€18.00€11.00€6.302
Jul ’23€5.26
€14.50
+175.7%
24.1%€18.00€11.00€6.552
Jun ’23€5.47
€16.25
+197.1%
10.8%€18.00€14.50€6.612
May ’23€5.60
€16.25
+190.2%
10.8%€18.00€14.50€8.882
Apr ’23€7.60
€16.25
+113.8%
10.8%€18.00€14.50€9.812

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.


Discover undervalued companies

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.